

# Mary Evelyn Flowers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7961802/publications.pdf>

Version: 2024-02-01

85  
papers

17,101  
citations

61687

45  
h-index

66518

82  
g-index

85  
all docs

85  
docs citations

85  
times ranked

9339  
citing authors

#	ARTICLE	IF	CITATIONS
1	Naive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2022, 40, 1174-1185.	0.8	36
2	Intensive chemotherapy for acute myeloid leukemia relapse after allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	3
3	Neuropathy and Muscle Cramps in Autologous and Allogeneic Hematopoietic Cell Transplantation Survivors. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 608.e1-608.e9.	0.6	5
4	Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 163.e1-163.e7.	0.6	0
5	Social support as a moderator of healthcare adherence and distress in long-term hematopoietic cell transplantation survivors. <i>Journal of Cancer Survivorship</i> , 2021, 15, 866-875.	1.5	6
6	Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12Months. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101253.	0.7	3
7	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.	2.5	8
8	Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 759.e1-759.e8.	0.6	8
9	Azithromycin Use and Increased Cancer Risk among Patients with Bronchiolitis Obliterans after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 392-400.	2.0	23
10	Who Enrolls in an Online Cancer Survivorship Program? Reach of the INSPIRE Randomized Controlled Trial for Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1948-1954.	2.0	6
11	Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil. <i>Pediatric Transplantation</i> , 2020, 24, e13789.	0.5	3
12	Dickkopf-related protein 3 is a novel biomarker for chronic GVHD after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 2409-2417.	2.5	14
13	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen mismatched donors. <i>Blood</i> , 2020, 136, 1499-1506.	0.6	16
14	Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1784-1802.	2.0	14
15	Late infectious complications in hematopoietic cell transplantation survivors: a population-based study. <i>Blood Advances</i> , 2020, 4, 1232-1241.	2.5	16
16	Brazilian Nutritional Consensus in Hematopoietic Stem Cell Transplantation: Graft- versus -host disease. <i>Einstein (Sao Paulo, Brazil)</i> , 2020, 18, eAE4799.	0.3	5
17	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , the, 2019, 6, e409-e418.	2.2	84
18	Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. <i>Blood Advances</i> , 2019, 3, 2764-2777.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e46-e54.	2.0	24
20	Ocular graft-versus-host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2019, 54, 662-673.	1.3	48
21	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
22	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
23	Engagement with INSPIRE, an Online Program for Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1692-1698.	2.0	14
24	An online randomized controlled trial, with or without problem-solving treatment, for long-term cancer survivors after hematopoietic cell transplantation. <i>Journal of Cancer Survivorship</i> , 2018, 12, 560-570.	1.5	56
25	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	0.6	52
26	Association of Plasma CD163 Concentration with De Novo Onset Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1250-1256.	2.0	38
27	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	0.6	43
28	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. <i>Blood</i> , 2016, 127, 1502-1508.	0.6	174
29	Special Considerations for Long-Term Survivors After Hematopoietic Stem Cell Transplantation. , 2016, , 951-962.		0
30	Genetic risk factors for sclerotic graft-versus-host disease. <i>Blood</i> , 2016, 128, 1516-1524.	0.6	18
31	Translation, Cross-Cultural Adaptation, and Validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in a Brazilian Population. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1313-1318.	2.0	3
32	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. <i>Clinical Cancer Research</i> , 2016, 22, 319-327.	3.2	68
33	How we treat chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 606-615.	0.6	275
34	Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2015, 100, 690-695.	1.7	29
35	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2014 Biomarker Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 780-792.	2.0	124
36	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 984-999.	2.0	293

#	ARTICLE	IF	CITATIONS
37	Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices. <i>Clinical Infectious Diseases</i> , 2015, 61, 31-39.	2.9	114
38	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1.	2.0	2,636
39	Association of severity of organ involvement with mortality and recurrent malignancy in patients with chronic graft-versus-host disease. <i>Haematologica</i> , 2014, 99, 1618-1623.	1.7	29
40	Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2014, 124, 1363-1371.	0.6	86
41	Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1996-2003.	2.0	51
42	Late Cardiovascular Complications after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 794-800.	2.0	84
43	Outcomes of Lung Transplantation after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1169-1175.	2.0	43
44	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. <i>Haematologica</i> , 2014, 99, 1624-1631.	1.7	33
45	Analysis of Gastrointestinal and Hepatic Chronic Graft-versus-Host Disease Manifestations on Major Outcomes: A Chronic Graft-versus-Host Disease Consortium Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 784-791.	2.0	43
46	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	0.8	197
47	Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 5098-5103.	0.6	93
48	Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. <i>Blood</i> , 2013, 121, 2340-2346.	0.6	55
49	Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. <i>Blood</i> , 2012, 120, 2545-2552.	0.6	101
50	Poor Agreement between Clinician Response Ratings and Calculated Response Measures in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1649-1655.	2.0	22
51	Clinical Benefit of Response in Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1517-1524.	2.0	47
52	Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 124-132.	2.0	26
53	Factors Associated with Adherence to Preventive Care Practices among Hematopoietic Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 995-1003.	2.0	53
54	Progressive Improvement in Cutaneous and Extracutaneous Chronic Graft-versus-Host Disease after a 24-Week Course of Extracorporeal Photopheresis—Results of a Crossover Randomized Study. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1775-1782.	2.0	127

#	ARTICLE	IF	CITATIONS
55	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011, 117, 6714-6720.	0.6	128
56	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. <i>Blood</i> , 2011, 117, 3214-3219.	0.6	544
57	Treatment of chronic graft-versus-host disease: Past, present and future. <i>The Korean Journal of Hematology</i> , 2011, 46, 153.	0.7	74
58	Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2011, 118, 456-463.	0.6	75
59	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011, 118, 4242-4249.	0.6	196
60	Treatment of chronic graft-versus-host disease in 2011. <i>Current Opinion in Hematology</i> , 2011, 18, 414-420.	1.2	66
61	Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2010, 28, 1011-1016.	0.8	321
62	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082.	0.6	143
63	Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. <i>Blood</i> , 2009, 114, 702-708.	0.6	218
64	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 641-650.	2.0	1,525
65	Treatment Change as a Predictor of Outcome among Patients with Classic Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1380-1384.	2.0	49
66	Recognizing and Managing Chronic Graft-Versus-Host Disease. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 134-141.	0.9	191
67	A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. <i>Blood</i> , 2008, 112, 2667-2674.	0.6	320
68	Use of Fluid-Ventilated, Gas-Permeable Scleral Lens for Management of Severe Keratoconjunctivitis Sicca Secondary to Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1016-1021.	2.0	115
69	Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 252-266.	2.0	445
70	Ancillary Therapy and Supportive Care of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 375-396.	2.0	316
71	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 491-505.	2.0	165
72	Cevimeline Reduced Mouth Dryness and Increased Salivary Flow in Patients with Xerostomia Complicating Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 792-794.	2.0	24

#	ARTICLE	IF	CITATIONS
73	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 945-956.	2.0	3,213
74	Duration of immunosuppressive treatment for chronic graft-versus-host disease. <i>Blood</i> , 2004, 104, 3501-3506.	0.6	269
75	Chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 215-233.	2.0	801
76	Evaluation of Thalidomide for Treatment or Prevention of Chronic Graft-versus-host Disease. <i>Leukemia and Lymphoma</i> , 2003, 44, 1141-1146.	0.6	25
77	Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. <i>Blood</i> , 2002, 100, 48-51.	0.6	263
78	Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. <i>Blood</i> , 2002, 100, 415-419.	0.6	403
79	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001, 97, 3390-3400.	0.6	1,306
80	Thalidomide for treatment of patients with chronic graft-versus-host disease. <i>Blood</i> , 2000, 96, 3995-3996.	0.6	122
81	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 1997, 90, 4705-4709.	0.6	303
82	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997, 89, 3880-3887.	0.6	3
83	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 1997, 90, 4705-4709.	0.6	7
84	Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. <i>British Journal of Haematology</i> , 1996, 92, 699-706.	1.2	48
85	Delayed Nonmalignant Complications after Hematopoietic Cell Transplantation. , 0, , 1620-1637.		4